<産業資料/調査レポートの題名> 2022年7月17日

世界の女性健康管理市場:薬物別(プロリア、デノスマブ、エビスタ、ミレーナ、ゾメタ、リクラスト、ヌバリング、プレマリン、アクトン)、用途別(女性不妊、閉経後骨粗鬆症、子宮内膜症、避妊、PCOS、閉経)


◆英文タイトル:Women's Health Care Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) - Global forecast to 2024

1 Introduction (Page No. – 17)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. – 20)
2.1 Research Data
2.1.1 Secondary Sources
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Sources
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimations
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study
3 Executive Summary (Page No. – 28)
4 Premium Insights (Page No. – 31)
4.1 Women’s Healthcare Market Overview
4.2 Market, By Drug (2019–2024)
4.3 Market, By Application (2019 vs 2024)
4.4 Market: Geographic Growth Opportunities
5 Market Overview (Page No. – 35)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Growing Incidence of Chronic Health Conditions Among Women
5.2.1.2 Demand for Contraceptives to Prevent Unintended Pregnancies
5.2.1.3 Government Initiatives to Curb Population Growth
5.2.1.4 Growing Focus on Product R&D
5.2.2 Market Opportunities
5.2.2.1 Emerging Markets
5.2.3 Market Challenges
5.2.3.1 Reluctance to Use Contraceptives
5.2.3.2 Market, By Drug
5.3 Introduction
5.4 Prolia
5.4.1 Prolia Accounts for the Largest Share of the Market
5.5 Xgeva
5.5.1 Xgeva is Primarily Marketed in the US and European Countries
5.6 Forteo
5.6.1 Eli Lilly is Expected to Experience A Revenue Decline in the Coming Years Due to the Patent Expiry of Forteo
5.7 Mirena
5.7.1 Mirena is Widely Accepted Amongst End Users Owing to the Minimal Side-Effects Associated With It
5.8 Nuvaring
5.8.1 Nuvaring is One of the Top-Selling Drugs From Merck (US) in the Women’s Health Category
5.9 Premarin
5.9.1 Premarin is Used for the Treatment of Osteoporosis in Women
5.10 Ortho Tri-Cy Lo (28)
5.10.1 Growing Number of Anda to Market Generic Versions of Ortho Tri-Cy Lo (28) to Hamper Its Sales in the Coming Years
5.11 Evista
5.11.1 Intense Generic Competition has Led to A Year-On-Year Decline in Evista’s Sales
5.12 Reclast/Aclasta
5.12.1 Aclasta has More Benefits as Compared to Other Drugs
5.13 Zometa
5.13.1 Early Patent Expiry of Zometa in the US and Europe has Affected Its Sales
5.14 Minastrin 24 FE
5.14.1 Availability of Low-Priced Generic Versions of Minastrin 24 FE is One of the Main Reasons for the Lower Sales of This Drug
5.15 Actonel
5.15.1 Intense Competition in the Osteoporosis Market has Led to A Sales Decline in Actonel in the Last Few Years
5.16 Pipeline Drugs
6 Women’s Healthcare Market, By Application (Page No. – 65)
6.1 Introduction
6.2 Postmenopausal Osteoporosis
6.2.1 High Prevalence of Osteoporosis in Women has Prompted Companies to Focus on This Therapeutic Area
6.3 Contraceptives
6.3.1 Benefits Offered By Contraceptives Driving Their Demand Among End Users
6.4 Menopause
6.4.1 Demand for Non-Hormonal Therapies has Increased Over the Last Few Years
6.5 Hormonal Infertility
6.5.1 Increasing Awareness About Ovulation Health to Support Market Growth
6.6 Polycystic Ovary Syndrome
6.6.1 Growing Prevalence of Pcos is Responsible for the Market Growth
6.7 Endometriosis
6.7.1 Orilissa is the First and Only Oral Treatment Specifically Available for Women With Endometriosis Pain
6.8 Other Applications
7 Women’s Healthcare Market, By Region (Page No. – 79)
7.1 Introduction
7.2 North America
7.2.1 US
7.2.1.1 Strong Economy and High Contraception Awareness are Key Factors Driving Market Growth in the US
7.2.2 Canada
7.2.2.1 Growing Prevalence of Pcos and Obesity to Support the Market Growth in Canada
7.3 Europe
7.3.1 Germany
7.3.1.1 Germany Holds the Largest Share of the Market in Europe
7.3.2 UK
7.3.2.1 Government Support and Favorable Training Programs are Major Market Drivers in the UK
7.3.3 France
7.3.3.1 High Prevalence of Lifestyle Disorders Among Women in France to Support the Market Growth
7.3.4 Spain
7.3.4.1 Improved Healthcare Expenditure to Support the Market in Spain
7.3.5 Italy
7.3.5.1 Relatively High Awareness of Contraceptives to Drive Market Growth in Italy
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.1.1 Japan Dominates the APAC Market for Women’s Healthcare
7.4.2 China
7.4.2.1 Growing Population and Urbanization are Factors Responsible for the Growth of the Market in China
7.4.3 India
7.4.3.1 Increasing Government Initiatives to Curb Population Growth Will Drive Market Growth in India
7.4.4 Rest of APAC
7.5 Latin America
7.5.1 Increasing Lifestyle Diseases and Awareness Among Women to Drive Market Growth in Latin America
7.6 Middle East & Africa
7.6.1 Increasing Government Initiatives to Curb Population Growth Will Drive Market Growth in India
8 Competitive Landscape (Page No. – 110)
8.1 Overview
8.2 Market Share Analysis
8.3 Competitive Leadership Mapping
8.3.1 Visionary Leaders
8.3.2 Dynamic Differentiators
8.3.3 Innovators
8.3.4 Emerging Players
9 Company Profiles (Page No. – 114)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
9.1 Bayer AG
9.2 Allergan
9.3 Merck & Co
9.4 Pfizer
9.5 Amgen
9.6 Agile Therapeutics
9.7 Ferring Pharmaceuticals
9.8 Mylan NV
9.9 Lupin Limited
9.10 Blairex Laboratories, Inc.
9.11 Apothecus Pharmaceutical Corporation
9.12 Eli Lilly and Company
9.13 Novartis AG
9.14 Johnson & Johnson Services Inc.
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.
10 Appendix (Page No. – 140)
10.1 Discussion Guide
10.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
10.3 Available Customizations
10.4 Related Reports
10.5 Author Details


LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark